Mesoblast Update on COVID-19 ARDS Trial
Filed with ASX · · 2 pages · English
Melbourne, Australia; December 18, and New York, USA; December 17, 2020: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today provided an update on the randomized controlled trial of remestemcel-L in ventilator-dependent patients with moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection after the Data Safety Monitoring Board (DSMB) performed a third interim analysis on
Story so far
Earlier from Mesoblast
- Trading halt
- Mesoblast Phase 3 Chronic Heart Failure Results
- Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS
- Novartis and Mesoblast Remestemcel-L Collaboration
- First Quarter Results Presentation
Later from Mesoblast
- Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF
- Mesoblast Phase 3 Chronic Low Back Pain Results
- Mesoblast Raises US$110M Led By US Strategic Investor Group
- COVID ARDS Trial Topline 60-Day Results
- MSB Reports Q3 Financial Results and Operational Highlight
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast